1. Transparency in Reimbursement Decisions: In Whose Best Interest?

   • Tania Stafinski
   • Devidas Menon

   Commentary 28 May 2014 Pages: 725 - 727

2. Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-Effectiveness Analysis in the USA?

   • James D. Chambers

   Current Opinion 24 May 2014 Pages: 729 - 733

3. Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider

   • Matt D. Stevenson
   • Peter L. Selby

   Practical Application 09 April 2014 Pages: 735 - 743

4. Economic Evaluations of Gastroesophageal Reflux Disease Medical Management

   • Andrew J. Gawron
   • Dustin D. French
   • Colin W. Howden

   Systematic Review 08 May 2014 Pages: 745 - 758

   

5. A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis

   • Ayse Kuspinar
   • Nancy E. Mayo

   Systematic Review 21 May 2014 Pages: 759 - 773

   

6. Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

   • Alex Diamantopoulos
   • A. Finckh
   • F. Dejonckheere

   Original Research Article Open access 23 May 2014 Pages: 775 - 787

   

7. The Better than Dead Method: Feasibility and Interpretation of a Valuation Study

   • R. A. van Hoorn
   • A. R. T. Donders
   • P. F. M. Stalmeier

   Original Research Article 21 May 2014 Pages: 789 - 799

   

8. A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding

   • Rosarin Sruamsiri
   • Piyameth Dilokthornsakul
   • Nathorn Chaiyakunapruk

   Original Research Article 22 May 2014 Pages: 801 - 813